B. Lactis lafti® B94 is now GRAS

摘要

One of Lallemand Health Solution's documented strains, Bifidobacterium lactis LaftI® B94 has recently received a No Questions Letter (NQL) regarding the Generally Recognized as Safe (GRAS) notification from the United States Food and Drug Administration (FDA), meaning it is recognized to be safe to be used in infants, as an ingredient in powdered milk-based infant formula. "This is such an honour that a premier regulatory authority like the US FDA has reviewed the strong body of clinical and scientific evidence demonstrating the safety of our strain Lafti® B94 and were satisfied. We are sincerely proud given the level of evidence needed in order to use probiotics in such a high risk vulnerable population, infants", happily states Solange Henoud, Global Regulatory Affairs Director at Lallemand Health Solutions Inc.